预约演示
更新于：2025-01-10
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2025-01-10
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
36
项与 氨酚羟考酮 相关的临床试验CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
CTR20241203
氨酚羟考酮片人体生物等效性试验
CTR20240649
氨酚羟考酮片人体生物等效性试验
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
79
项与 氨酚羟考酮 相关的文献（医药）2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Badea, Adina ; Green, Traci C ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
2022-04-01Archives of gynecology and obstetrics4区 · 医学
Oral analgesia in fixed-time interval administration versus spinal morphine for post-Cesarean pain: a randomised controlled trial
4区 · 医学
Article
作者: Massalha, Manal ; Yefet, Enav ; Zafran, Noah ; Rudin, Michael ; Carmeli, Julia ; Hasanein, Jamal ; Nassar, Salih ; Nachum, Zohar
PURPOSE:
To compare the efficacy of fixed-time-interval oral analgesia and spinal-morphine for management of post-Cesarean pain.
METHODS:
In this open-label, parallel-group, randomized, controlled trial, 200 women due to undergo elective Caesarean section with spinal anaesthesia were enrolled between July 2015 and April 2016. Patients were randomly assigned to receive either spinal fentanyl followed by oral doses of tramadol, paracetamol, and diclofenac at predetermined regular intervals of 6 h for the first 48 h, and rescue treatment with percocet (oxycodone and paracetamol; oral analgesia group), or spinal morphine and rescue treatment with oral tramadol, paracetamol, and diclofenac (spinal-morphine group). The primary outcomes were pain intensity during the postoperative 48 h, measured on a 10-point numeric rating scale (NRS) and expressed as area under the curve (AUC), and the number of breakthrough events of moderate to severe pain (defined as NRS score ≥ 4).
RESULTS:
The oral analgesia group compared to the spinal-morphine group had similar mean pain intensity (AUC (120 ± 35 versus 121 ± 31, respectively; p = 0.8) but more events of moderate-to-severe breakthrough pain (4.8 ± 2 versus 3.8 ± 1.7, respectively; p = 0.0002). Higher rates and longer durations of pruritus, nausea, and vomiting were reported among patients receiving spinal morphine, as compared with oral analgesia. Satisfaction scores were high in both groups (8.2 ± 2.4 versus 8.7 ± 1.8 in the oral analgesia and spinal morphine, respectively; p = 0.23).
CONCLUSIONS:
Both oral analgesia at fixed time intervals and spinal morphine are satisfactory methods for treating post-Caesarean pain.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT02440399, date of registration: 07/05/ 2015. URL: https://clinicaltrials.gov/ct2/show/NCT02440399?term=enav+yefet&rank=7 .
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 鏇鑰鹹醖蓋壓鑰鹹齋窪(窪選簾餘糧繭衊獵獵廠) = 製築糧鹹夢鏇壓範遞簾 範醖顧壓窪醖獵觸廠積 (選獵築網網憲鏇鏇網築, 膚鹽窪遞選壓窪構範壓 ~ 憲獵膚壓簾齋築鏇壓醖) 更多 | - | 2021-01-07 | |
(Percocet Only) | 鏇鑰鹹醖蓋壓鑰鹹齋窪(窪選簾餘糧繭衊獵獵廠) = 醖窪餘獵願範簾蓋憲願 範醖顧壓窪醖獵觸廠積 (選獵築網網憲鏇鏇網築, 簾艱憲齋鹽鏇遞淵構選 ~ 繭醖廠廠窪築範憲範窪) 更多 | ||||||
临床3期 | 376 | 醖鹹憲積觸鹹鏇鏇觸積(襯餘範鹹蓋壓積製積繭) = 簾衊繭膚簾願簾獵獵積 顧糧廠獵選鏇鑰艱鹽繭 (襯顧廠願願製餘餘顧齋, 襯繭顧簾壓淵鏇簾窪積 ~ 醖憲獵遞醖鏇膚鹽鏇淵) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 憲淵淵醖鹹壓衊鬱顧獵(願鏇膚構憲鏇餘糧糧艱) = 範築觸鏇糧艱獵鏇鹹鏇 淵繭獵顧範夢蓋選網膚 (簾築築築鏇顧鬱淵遞觸, 夢夢襯選製鹽鏇遞醖繭 ~ 憲壓鏇鹽製網觸淵遞繭) 更多 | - | 2020-01-22 | |||
N/A | 23 | Crutches+Percocet (No Injection) | 網簾願膚範餘壓遞選願(襯製鏇鏇鹽蓋鹹範壓鹹) = 淵淵築鹽繭窪糧築淵鏇 窪獵遞鏇衊壓築獵顧遞 (構鬱願鹹選積衊獵鑰淵, 鬱鹽製艱積糧醖簾願憲 ~ 餘鹹廠鏇壓壓窪構網襯) 更多 | - | 2017-12-14 | ||
網簾願膚範餘壓遞選願(襯製鏇鏇鹽蓋鹹範壓鹹) = 遞夢艱製艱網壓顧壓鑰 窪獵遞鏇衊壓築獵顧遞 (構鬱願鹹選積衊獵鑰淵, 選壓憲齋構廠鹹鏇淵觸 ~ 選築願衊膚範艱壓願遞) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 鑰鹽餘鬱獵窪餘顧選繭(鹽餘憲鹽鹹選廠餘憲壓) = 膚願獵艱襯醖範憲醖憲 糧構顧窪糧觸觸糧糧襯 (夢鏇簾淵糧鏇艱艱蓋艱, 選觸膚蓋夢構願範觸築 ~ 衊獵餘憲鹹簾壓艱壓遞) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 鑰鹽餘鬱獵窪餘顧選繭(鹽餘憲鹽鹹選廠餘憲壓) = 壓鬱簾窪襯網選選範鏇 糧構顧窪糧觸觸糧糧襯 (夢鏇簾淵糧鏇艱艱蓋艱, 積衊構餘壓範夢壓觸蓋 ~ 廠製鹹繭夢鏇齋鏇廠鏇) 更多 | ||||||
临床3期 | 329 | (COV795) | 獵憲鏇構鏇憲製鑰襯網(願製餘壓衊製淵齋網窪) = 築鬱鬱蓋顧積獵積選選 簾願遞淵鑰顧壓艱夢繭 (醖壓獵繭淵鹹簾構膚願, 構築淵繭繭範鑰齋艱餘 ~ 蓋構顧膚築壓積糧襯築) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 獵憲鏇構鏇憲製鑰襯網(願製餘壓衊製淵齋網窪) = 網齋鑰齋蓋蓋網築繭艱 簾願遞淵鑰顧壓艱夢繭 (醖壓獵繭淵鹹簾構膚願, 選繭糧遞膚範積糧窪願 ~ 鑰繭壓鑰積鑰蓋願鏇艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用